Goldman Sachs starts Sandoz with 'buy' on its patent rights position

Sandoz AG

01/04/2026 09:51

** Goldman Sachs starts Sandoz SDZ.S with a "buy" rating due to the Swiss pharmaceutical company's patent rights position

** The broker projects an increase in Sandoz's profits in the next 10 years as the company is not exposed to an upcoming wave of patent right expirations

** GS points to the expertise reflected in a best-in-class portfolio and a proven track record of first wave launches with up to 32 assets in Sandoz's development pipeline

** Sandoz shares edge up about 4%, in a generally positive market, making it to the top of the Swiss small cap index .SMIM

(Reporting by Simon Ferdinand Eibach)

((Simonferdinand.eibach@thomsonreuters.com))